Abstract: The present invention refers to a novel medical use of the (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13,13a-decahydro-3-methoxy-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]naphthyridine compound [CAS-186002-54-0], known in the literature under code RS-79948-197, i.e., to its use in the treatment of psychoses. In particular, the present invention refers to the RS-79948-197 compound as an atypical antipsychotic for use in the treatment of psychoses, in particular of schizophrenia. Furthermore, the present invention refers to a pharmaceutical composition comprising the RS-79948-197 compound for use in the treatment of psychoses, in particular of schizophrenia.

Abstract: A pharmaceutical composition is characterized by: an active principle selected from one or more components of the group consisting of R(−)-propylnorapomorphine hydrochloride, S(+)-propylnorapomorphine hydrochloride, derivatives of R(−)-propylnorapomorphine hydrochloride and derivatives of S(+)-propylnorapomorphine hydrochloride, in pharmaceutically acceptable and effective doses, and further comprising components selected from the group consisting of stabilizers, solubilizers and permeation activators to facilitate the passage of the active principle through the skin. A transdermal patch that includes the pharmaceutical composition is also disclosed as well as a method of treatment for Parkinson's disease, hemicrania, sexual impotence, and psychotic disorders using the pharmaceutical composition or a transdermal patch that includes the pharmaceutical composition are described.

Abstract: The use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions useful for the release form ethyl alcohol consumption and the compostions obtained.